Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.35 |
| ▸ | PDE4A | P27815 | 7/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16682874 | 0.92 | GSK3A (0.39) | PDE10AHKDC1CHRM3PDE4APDE4B | |
| SCHEMBL21573272 | 0.90 | GSK3A (0.40) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL24499953 | 0.87 | LMNA (0.35) | PDE10ALDHA | |
| SCHEMBL13033012 | 0.84 | PDE10A (0.50) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL1286191 | 0.84 | CHRM3 (0.41) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL12090397 | 0.77 | IKBKB (0.41) | — | |
| SCHEMBL21211777 | 0.77 | PDE10A (0.43) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL24500132 | 0.77 | PDE10A (0.43) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL18069346 | 0.76 | PDE10A (0.41) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL28979288 | 0.76 | HTT (0.43) | PDE10ACHRM3PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0007466-B1 | 2-CYCLOPROPYL-PYRIMIDIN(4)YL-THIONOPHOSPHONIC ACID ESTERS, PROCESS FOR THEIR PRODUCTION, THEIR UTILISATION AS INSECTICIDES AND ACARICIDES, PESTICIDAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESS FOR THE PRODUCTION OF THE PESTICIDAL COMPOSITIONS | BAYER AG (DE) | 1981-04-15 | — | — | EP | claimed |
| EP-0007466-A1 | 2-Cyclopropyl-pyrimidin(4)yl-thionophosphonic acid esters, process for their production, their utilisation as insecticides and acaricides, pesticidal compositions containing these compounds and process for the production of the pesticidal compositions | BAYER AG (DE) | 1980-02-06 | — | — | EP | claimed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | Mirati Therapeutics, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2025043191-A1 | PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE | ORIC PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | ORIC PHARMACEUTICALS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-12109198-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| EP-0185778-A1 | Method and composition for enhancing the insecticidal activity of certain organophosphorus compounds | THE DOW CHEMICAL COMPANY (US) | 1986-07-02 | — | — | EP | disclosed |
| US-4489068-A | Method and composition for enhancing the insecticidal activity of certain organophosphorus compounds | THE DOW CHEMICAL COMPANY (US) | 1984-12-18 | — | — | US | disclosed |
| US-4486421-A | SYSTEMIC | THE DOW CHEMICAL COMPANY (US) | 1984-12-04 | — | — | US | disclosed |
| EP-0007466-B1 | 2-CYCLOPROPYL-PYRIMIDIN(4)YL-THIONOPHOSPHONIC ACID ESTERS, PROCESS FOR THEIR PRODUCTION, THEIR UTILISATION AS INSECTICIDES AND ACARICIDES, PESTICIDAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESS FOR THE PRODUCTION OF THE PESTICIDAL COMPOSITIONS | BAYER AG (DE) | 1981-04-15 | — | — | EP | disclosed |
| US-4254113-A | Combating arthropods with O-Alkyl-O-(2-cyclopropyl-6-methyl-pyrimidin-4-yl)-thionophosphonic acid esters | BAYER AKTIENGESELLSCHAFT (DE) | 1981-03-03 | — | — | US | disclosed |
| EP-0007466-A1 | 2-Cyclopropyl-pyrimidin(4)yl-thionophosphonic acid esters, process for their production, their utilisation as insecticides and acaricides, pesticidal compositions containing these compounds and process for the production of the pesticidal compositions | BAYER AG (DE) | 1980-02-06 | — | — | EP | disclosed |
| EP-0007466-A1 | 2-Cyclopropyl-pyrimidin(4)yl-thionophosphonic acid esters, process for their production, their utilisation as insecticides and acaricides, pesticidal compositions containing these compounds and process for the production of the pesticidal compositions | BAYER AG (DE) | 1980-02-06 | — | — | EP | disclosed |
| US-4014879-A | RING CLOSURE, NEUTRALIZATION; AMIDINE AND METHYLACETOACETATE IN A BASE | CIBA-GEIGY CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-4012506-A | Pyrimidyl thio- and dithio-phosphoric acid esters | CIBA-GEIGY CORPORATION (US) | 1977-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12109198-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | EED, EZH2, BMI1 | PDE10A 4193/4885HKDC1 1356/4885CHRM3 2012/4885 |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | PDE10A 4260/4885HKDC1 3201/4885CHRM3 4839/4885 |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | PDE10A 4193/4885HKDC1 1356/4885CHRM3 2012/4885 |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | BMI1, EZH2, SUZ12 | PDE10A 4059/4885HKDC1 1942/4885CHRM3 4702/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | PDE10A 4449/4885HKDC1 2248/4885CHRM3 4739/4885 |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | BMI1, EZH2, SUZ12 | PDE10A 4059/4885HKDC1 1942/4885CHRM3 4702/4885 |
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | EZH2, BMI1, EZH1 | PDE10A 4230/4885HKDC1 3274/4885CHRM3 4839/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | PDE10A 4538/4885HKDC1 2347/4885CHRM3 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.